Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ACELYRIN, INC.
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease
October 16, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024
September 19, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive
September 10, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
August 22, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
August 13, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
August 06, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
June 05, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
May 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Leadership Transition
May 09, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
April 29, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
March 28, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease
March 20, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
March 11, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients
March 11, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications
February 15, 2024
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors
December 20, 2023
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
November 27, 2023
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
November 07, 2023
From
ACELYRIN, INC.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
November 06, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
October 31, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
October 03, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
September 11, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
August 14, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023
August 07, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer
July 18, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
June 15, 2023
From
Acelyrin, Inc.
Via
GlobeNewswire
Tickers
SLRN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.